Regeneron Pharmaceuticals Executives Conduct Major Stock Sales
| Reporter Name | Relationship | Type | Amount | SEC Filing |
|---|---|---|---|---|
| Schleifer Leonard S | Bd. Co-Chair, President & CEO | Sell | $22,355,714 | Form 4 |
| Yancopoulos George | Bd. Co-Chair, President & CSO | Sell | $48,793,727 | Form 4 |
| Yancopoulos George | Bd. Co-Chair, President & CSO | Sell | $48,636,545 | Form 4 |
Leonard S. Schleifer, the Bd. Co-Chair, President & CEO of Regeneron Pharmaceuticals, sold 22,830 shares of common stock on May 17, 2024, at weighted average prices of $979.22 and $980.07, totaling approximately $22,355,714. Following these transactions, Schleifer directly owns 466,877 shares and indirectly owns 228,469 shares through various means including a 2023 GRAT, 401(k) Plan, and Trust.
George Yancopoulos, Bd. Co-Chair, President & CSO of Regeneron Pharmaceuticals, conducted two separate sales of company stock. On May 15, 2024, he sold 50,000 shares with transaction prices ranging from $965.69 to $989.14, totaling $48,793,727. Following this sale, Yancopoulos directly owns 836,383 shares and indirectly owns 362,461 shares through various trusts and plans. On May 16, 2024, he sold another 50,000 shares at weighted average prices ranging from $967.4 to $978.18, totaling $48,636,545. After these transactions, Yancopoulos directly owns 786,383 shares and indirectly owns the same amount through various trusts and plans.